contraindications for glp-1 agonists include Receptor the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Non-insulin injectable antidiabetic drugs -

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Pharmaceutical giant Eli Lilly saw its stock jump Thursday morning after announcing initial Phase 3 trial results on orforglipron, a highly anticipated medication for diabetes and weight loss

Answer a few questions about your health history, current goals, and any symptoms you may be experiencing

Johnson JA, Simpson SH, Toth EL, Majumdar SR: Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

The observed weight loss might not be as high as with some of the newer injectable GLP-1 medications, he says, but the oral pills offer the potential of having an inexpensive, accessible drug. Both pills must be taken daily, whereas many GLP-1 injections are weekly